Ted Kellner Issues Letter to AIM ImmunoTech (AIM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed
December 11, 2024 7:30 AM ESTIncumbent Boards Claims of Progress Are Not Credible or Supported by Data
AIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDA
According to ISS The lack of transparency gives the impression that the companys pipeline is more advanced and that the company is more involved than it actually is1
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with... More
